Direct Biologics
Blood & Organ Banks · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
5301 SW Pkwy Ste 415 Bldg 1, Austin, Tex...Website
www.directbiologics.comRevenue
<$5 MillionIndustry
ZI Rank: 3
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
4
5
5
5
13
3
About Direct Biologics
Direct Biologics is a market leading innovator and science-based cGMP manufacturer of regenerative biologic products. The Company is committed to providing the latest clinical and scientific information through rigorous and thorough research. With deep knowledge and industry expertise in cellular and regenerative therapies, the company has brought to market a significant development in therapeutic biologics with the introduction of the highest quality production of extracellular vesicles. Direct Biologics was created to expand the science of cutting-edge human cell and tissue technologies through research and has built extensive intellectual property surrounding stem cells and their utility. Direct Biologics is committed to patient safety. All regulated processes are compliant with cGxP to ensure the highest safety and quality throughout every stage of our product. Direct Biologics provides quality products for healthcare providers and patients. Exceptional quality standards are maintaRead more
Direct Biologics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Direct Biologics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Direct Biologics launches new products
Website visits: Recent activity has been detected on your website
Check if Direct Biologics has recently received funding, and reach out quickly before it becomes old news!
Direct Biologics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Direct Biologics had a recent Job posting/layoffs
Earning: See what the market has to say on Direct Biologics recently announced quarterly report
Check out if Direct Biologics is spiking on competitors!
Funding: Get notified immidiatlly once Direct Biologics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Direct Biologics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Direct Biologics
Compare insights from companies similar to Direct Biologics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Direct Biologics is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Direct Biologics is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Direct Biologics.
Direct Biologics financials insights
Gather financial insights about Direct Biologics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$350K
Direct Biologics Tech Stack
A closer look at the technologies used by Direct Biologics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Hiring Plans
Direct Biologics is hiring in Operations for the first time in 12 months.
Hiring Plans
New Hire
Executive Move
Direct Biologics News & Media
Direct Biologics Receives FDA Clearance to Initiate Phase 1b/2a Clinical Trial of ExoFlo™ in Patients with Medically Refractory Perianal Fistulizing Crohn’s Disease
AUSTIN, Texas--(BUSINESS WIRE)--Direct Biologics, LLC, a late-stage biotechnology company leveraging its regenerative medicine platform using extracellular vesicles (EVs) secreted from bone marrow-derived mesenchymal stem cells (MSCs) to address multiple disease indications, announces U.S. Food and Drug Administration (FDA) clearance of the Company’s investigational new drug (IND) application for a Phase 1b/2a clinical trial to evaluate the safety and efficacy of ExoFlo™ for the treatment of meCORRECTING and REPLACING Direct Biologics Reports Compelling Data as ExoFlo™ Expanded Access Program in Hospitalized COVID-19 Patients with Moderate-to-Severe ARDS Surpasses 100 Subjects
AUSTIN, Texas--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions. The updated release reads: DIRECT BIOLOGICS REPORTS COMPELLING DATA AS EXOFLO™ EXPANDED ACCESS PROGRAM IN HOSPITALIZED COVID-19 PATIENTS WITH MODERATE-TO-SEVERE ARDS SURPASSES 100 SUBJECTS Company’s Phase 3 EXTINGUISH ARDS trial is enrolling hospitalized patients with moderate-to-severe ARDS regardless of underlying etiology Direct Biologics, LLC, a late-stage biotechnologyDirect Biologics Reports Compelling Data as ExoFlo™ Expanded Access Program in Hospitalized COVID-19 Patients with Moderate-to-Severe ARDS Surpasses 100 Subjects
AUSTIN, Texas--(BUSINESS WIRE)--Direct Biologics, LLC, a late-stage biotechnology company leveraging its regenerative medicine platform using extracellular vesicles (EVs) secreted from bone marrow-derived mesenchymal stem cells to address multiple disease indications, announces favorable safety and efficacy data from its ExoFlo™ expanded access program in hospitalized adult COVID-19 patients with moderate-to-severe acute respiratory distress syndrome (ARDS). “We are pleased to report compellingDirect Biologics Announces FDA Authorization to Expand Ongoing Phase 3 Clinical Study of ExoFlo™ to All-Cause Moderate-to-Severe ARDS
AUSTIN, Texas--(BUSINESS WIRE)--Direct Biologics, LLC, a late-stage biotechnology company leveraging its regenerative medicine platform using extracellular vesicles (EVs) secreted from bone marrow-derived mesenchymal stem cells to address multiple disease indications, announces that the U.S. Food and Drug Administration (FDA) has authorized the expansion of its pivotal Phase 3 EXTINGUISH ARDS trial to evaluate the safety and efficacy of ExoFlo™ in the treatment of moderate-to-severe acute respi
Read more news
Top Blood & Organ Banks Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Direct Biologics
Sign Up For FreeTo access detailed company insights
Direct Biologics is a market leading innovator and science-based cGMP manufacturer of regenerative biologic products. The Company is committed to providing the latest clinical and scientific information through rigorous and thorough research. With deep knowledge and industry expertise in cellular and regenerative therapies, the company has brought... Read More
